Degarelix treatment increased the fraction of NEPC tumor area and ASCL1+ tumor cells and decreased the fraction of AR+ tumor cells relative to vehicle treated RPM SQ tumors (Extended Data Fig. 8k). This evidence concerns the gene AR and neoplasm.